Drug profile · INN
methenamine hippurate
APOHEALTH URINARY TRACT ANTIBACTERIAL
methenamine hippurate (APOHEALTH URINARY TRACT ANTIBACTERIAL) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — methenamine hippurate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
methenamine hippurate (APOHEALTH URINARY TRACT ANTIBACTERIAL) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methenamine hippurate?
methenamine hippurate (APOHEALTH URINARY TRACT ANTIBACTERIAL) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for methenamine hippurate?
APOHEALTH URINARY TRACT ANTIBACTERIAL is a marketed brand name for methenamine hippurate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methenamine hippurate?
methenamine hippurate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.